Abstract: FR-PO027
Outcomes Among Hospitalized Patients With COVID-19 and AKI: Role of SARS-CoV-2 Vaccine
Session Information
- COVID-19: AKI Outcomes, Biomarkers, Treatments, Case Reports
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Torres Cuevas, Jose Luis, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Martinez-Sanchez, Froylan David, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Gonzalez Sanchez, Hector Raul, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Saenz-Ancira, Santiago, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Reyna Juárez, Yatzil, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Diaz-Jarquin, Alejandra, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Romero-Reyes, Carlos Alberto, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Ibarra Santoyo, Luis Alberto, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Juarez, Joana Balderas, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Salinas-Ramirez, Mauricio Adrian, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
- Tenorio-Aguirre, Erika Karina, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
Background
COVID-19 and Acute kidney injury (AKI) are associated with increased mortality and worse kidney outcomes. Although vaccines against SARS-CoV-2 have decreased the rate COVID-19 morbimortality, the role of immune protection against SARS-CoV-2 in the setting of AKI has not been fully yielded
Methods
Retrospective case-control study that included clinical and biochemical data of 412 (78 vaccinated and 334 non-vaccinated) patients with severe COVID-19. Cox regression analyses were used to evaluate the effect of the vaccine in mortality and AKI outcomes
Results
The mean age of the patients was 55±15 years, 64% were women, the mean body mass index was 28±5 kg/m2, and median in-hospital stay was 10(6-16) days. The rate of mortality and AKI 3 was 29% vs 10% and 27% vs 13%, for unvaccinated and vaccinated patients, respectively. Cox proportional hazard ratios for survival and prevention of AKI are shown in table 1
Conclusion
The SARS-CoV-2 vaccine was independently associated with lower mortality and AKI progression in patients with severe COVID-19
Table 1. Cox proportional hazard model of SARS-CoV-2 vaccination and the risk for mortality, development of Acute Kidney Injury (AKI), and AKI stage 3
| Mortality | AKI 1-3* | AKI 3* | ||||
| SARS-CoV-2 Vaccine | HR (95%CI) | p value | HR (95%CI) | p value | HR (95%CI) | p value |
| Unadjusted | 0.382 (0.185-0.785) | 0.009 | 0.629 (0.441-0.897) | 0.010 | 0.528 (0.274-1.017) | 0.056 |
| Model 1 | 0.348 (0.168-0.719) | 0.004 | 0.597 (0.418-0.853) | 0.005 | 0.498 (0.256-0.967) | 0.040 |
| Model 2 | 0.440 (0.211-0.919) | 0.029 | 0.585 (0.407-0.842) | 0.004 | 0.464 (0.234-0.919) | 0.028 |
| Model 3 | 0.444 (0.213-0.927) | 0.031 | 0.534 (0.368-0.776) | 0.001 | 0.493 (0.246-0.985) | 0.045 |
Model 1 was adjusted by age, sex, and Body Mass Index; model 2 included model 1 plus type 2 diabetes, blood pressure >140/90 mmHg, chronic kidney disease, renal replacement therapy, and AKI 3; and model 3 included model 2 plus serum levels of D-dimer, lactic dehydrogenase, C-reactive protein, and ferritin. * In model 2 variable AKI 3 was not included in the Cox regression analysis.